Home News Info Guidelines Trials EUHASS Travel Products Organisations Genes QC FAQs About Links

Clinical Trials

Below is a list of active clinical trials worldwide which involve patients with inherited bleeding disorders. The link from each study title will take you to ClinicalTrials.gov which gives you more information about the trial.
To see a list of trials for a particular bleeding disorder use the drop-down list below to select the condition you're interested in. A new window will open up with a list of trials for this condition only.

Please select the category:
HEAD-US SCORING SYSTEM: Assessment of the Real-world Impact of Ultrasound
Condition:   Moderate and Severe Haemophilia
Intervention:   Other: HEAD-US scoring system
Sponsors:   Guy's and St Thomas' NHS Foundation Trust;   Pfizer
Not yet recruiting - verified July 2017
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
Condition:   Hemorrhagic Hereditary Telangiectasia (HHT)
Interventions:   Drug: Bevacizumab;   Drug: sodium chloride 0.9%
Sponsor:   Hospices Civils de Lyon
Not yet recruiting - verified July 2017
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Conditions:   Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions:   Drug: Concizumab;   Drug: Eptacog alfa
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017
Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients
Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Intervention:   Drug: turoctocog alfa
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified June 2017
Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery
Condition:   Factor 10 Deficiency
Intervention:   Drug: Coagadex
Sponsor:   Bio Products Laboratory
Not yet recruiting - verified July 2017
Factor XIII in Major Burns Coagulation
Conditions:   Burns;   Coagulation Disorder;   Factor XIII Deficiency;   Cicatrization;   Endothelial Dysfunction
Intervention:   Diagnostic Test: Coagulation tests
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Not yet recruiting - verified May 2017
Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies
Condition:   Hemophilia
Intervention:   Other: Non interventional study
Sponsor:   Nantes University Hospital
Recruiting - verified August 2017
China Registry for Genetic / Metabolic Liver Diseases
Condition:   Genetic/Metabolic Liver Diseases
Intervention:   Drug: Standard of care
Sponsors:   Beijing Friendship Hospital;   Beijing YouAn Hospital;   Henan Provincial Hospital;   Beijing Ditan Hospital;   Hebei Medical University Third Hospital;   Peking University First Hospital;   Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital;   Nanfang Hospital of Southern Medical University;   Affiliated Hospital, Logistics University of People's Armed Police Force;   Beijing Anzhen Hospital, Capital Medical University;   West China Second University Hospital of Sichuan University;   Jinshan Hospital of Fudan University;   Fudan University
Recruiting - verified April 2017
A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
Conditions:   Congenital Bleeding Disorder;   Haemophilia B
Interventions:   Drug: N9-GP;   Drug: ALPROLIX®
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017
Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients
Condition:   Antithrombin Deficiency Type 2
Intervention:   Drug: ATryn continuous infusion
Sponsors:   Mayo Clinic;   rEVO Biologics
Not yet recruiting - verified April 2017
Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency
Condition:   Factor VII Deficiency
Interventions:   Biological: Eptacog alfa, biosimilar and reference medicinal product Novoseven;   Biological: Eptacog alfa biosimilar
Sponsor:   AryoGen Pharmed Co.
Recruiting - verified March 2017
A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Conditions:   Haemophilia A;   Haemophilia B
Interventions:   Drug: ELOCTA;   Drug: ALPROLIX
Sponsor:   Swedish Orphan Biovitrum
Recruiting - verified May 2017
Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients
Condition:   Von Willebrand Diseases
Intervention:  
Sponsor:   University Hospital, Lille
Not yet recruiting - verified July 2017
A Gene Transfer Study for Hemophilia A
Condition:   Hemophilia A
Intervention:   Genetic: SPK-8011
Sponsor:   Spark Therapeutics
Recruiting - verified April 2017
Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A
Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Intervention:   Drug: turoctocog alfa pegol
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017
Fascial Therapy in Elbow Hemophilic Arthropathy
Condition:   Hemophilia
Intervention:   Other: Experimental group
Sponsor:   Real Fundación Victoria Eugenia
Not yet recruiting - verified January 2017
MRA With Feraheme in HHT
Condition:   Hereditary Hemorrhagic Telangiectasia
Intervention:   Procedure: Feraheme MRI/MRA
Sponsor:   University of California, Los Angeles
Recruiting - verified March 2017
Immunmodulation in Patients With HHT
Condition:   Hereditary Haemorrhagic Telangiectasia (HHT)
Intervention:   Other: blood sample
Sponsor:   University Hospital, Essen
Recruiting - verified December 2016
UK - EHL Outcomes Registry
Conditions:   Hemophilia A;   Hemophilia B
Intervention:  
Sponsor:   Royal Free Hospital NHS Foundation Trust
Not yet recruiting - verified October 2016
Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
Condition:   Hemophilia A
Interventions:   Drug: efmoroctocog alfa;   Drug: Factor VIII
Sponsor:   Swedish Orphan Biovitrum
Recruiting - verified February 2017
rVWF IN PROPHYLAXIS
Condition:   Von Willebrand Disease
Interventions:   Biological: von Willebrand factor (Recombinant);   Biological: Antihemophilic Factor (Recombinant)
Sponsor:   Baxalta US Inc.
Not yet recruiting - verified November 2016
Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Interventions:   Drug: turoctocog alfa;   Drug: turoctocog alfa
Sponsor:   Novo Nordisk A/S
Recruiting - verified July 2017
BAX 111 rVWF in Pediatrics
Condition:   Von Willebrand Disease
Interventions:   Biological: von Willebrand factor (Recombinant);   Biological: Antihemophilic Factor (Recombinant)
Sponsor:   Baxalta US Inc.
Not yet recruiting - verified October 2016
Graded TTCE for Post-Embolization PAVM Monitoring
Condition:   Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention:   Other: Transthoracic Contrast Echocardiogram
Sponsor:   University of Pennsylvania
Recruiting - verified August 2017
Low VW Activity in Adolescent HMB
Condition:   Von Willebrand Factor Deficiency
Interventions:   Other: Genetic Analysis;   Other: Medical Record Data Abstraction;   Other: Pictorial Blood Assessment Chart (PBAC) score;   Other: Complete Bleeding Symptom ISTH Bleeding Assessment Tool
Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Baxalta US Inc.
Recruiting - verified July 2017
Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A
Condition:   Hemophilia A
Interventions:   Drug: Recombinant Factor VIII (50 IU/kg);   Drug: Recombinant Factor VIII (On-demand treatment)
Sponsor:   Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting - verified October 2016
A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children
Condition:   Haemophilia
Intervention:   Other: Observe the patient's condition and then change the regimen
Sponsor:   Beijing Children's Hospital
Recruiting - verified December 2016
Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT
Conditions:   Hereditary Hemorrhagic Telangiectasia;   Epistaxis
Interventions:   Drug: Mupirocin;   Other: Placebo
Sponsor:   Hospital Italiano de Buenos Aires
Not yet recruiting - verified November 2016
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
Conditions:   Hereditary Hemorrhagic Telangiectasia;   Gastrointestinal Hemorrhage;   Anemia
Intervention:   Drug: Octreotide LAR
Sponsors:   Radboud University;   St. Antonius Hospital
Recruiting - verified August 2016
BAX 802 in CHA With Inhibitors
Condition:   Hemophilia A
Intervention:   Biological: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)
Sponsor:   Baxalta US Inc.
Recruiting - verified April 2017
Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
Condition:   Von Willebrand Disease
Intervention:   Other: Non interventional study
Sponsor:   Nantes University Hospital
Not yet recruiting - verified June 2016
Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia
Condition:   Haemophilia
Intervention:   Other: Patient questionnaire
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting - verified August 2016
The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children
Conditions:   Benign Hypermobility Syndrome;   Functional Constipation
Intervention:  
Sponsor:   Medical University of Warsaw
Recruiting - verified March 2017
Human Fibrinogen Concentrate in Pediatric Cardiac Surgery
Conditions:   Hypofibrinogenemia;   Afibrinogenemia;   Bleeding Disorders
Interventions:   Drug: RiaStAP;   Drug: Saline
Sponsor:   Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Recruiting - verified April 2017
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Condition:   Hemophilia A, Congenital
Intervention:   Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
Sponsor:   Bayer
Recruiting - verified July 2017
World Bleeding Disorders Registry
Condition:   Hemophilia A and B
Intervention:  
Sponsor:   World Federation of Hemophilia
Not yet recruiting - verified May 2016
TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia
Condition:   Haemophilia A
Intervention:   Other: Thrombin generation measurement.
Sponsor:   Hospices Civils de Lyon
Recruiting - verified February 2017
Low Von Willebrand in Ireland Cohort Study
Condition:   Von Willebrand Factor, Deficiency
Intervention:  
Sponsor:   St. James's Hospital, Ireland
Recruiting - verified May 2017
Investigation of the Genetics of Hematologic Diseases
Conditions:   Bone Marrow Failure Syndromes;   Erythrocyte Disorder;   Leukocyte Disorder;   Hemostasis;   Blood Coagulation Disorder;   Sickle Cell Disease;   Dyskeratosis Congenita;   Diamond-Blackfan Anemia;   Congenital Thrombocytopenia;   Severe Congenital Neutropenia;   Fanconi Anemia
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   Boston Children’s Hospital
Recruiting - verified September 2016
Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients
Conditions:   Hemophilia A;   Factor VIII
Intervention:   Drug: Recombinant VIII factor
Sponsor:   Hospital Universitario La Fe
Recruiting - verified August 2016
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Condition:   Acquired Hemophilia A
Intervention:   Biological: OBIZUR
Sponsor:   Baxalta US Inc.
Recruiting - verified August 2016
Weight-based Dosing in Hemophilia A
Condition:   Hemophilia
Intervention:   Drug: rFVIII
Sponsor:   University of Pittsburgh
Recruiting - verified May 2017
Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease
Condition:   Type 1 Von Willebrand Disease
Interventions:   Drug: recombinant von Willebrand factor;   Drug: tranexamic acid
Sponsors:   University of Pittsburgh;   University of North Carolina;   Carnegie Mellon University;   Duke University
Not yet recruiting - verified August 2017
Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Conditions:   Hereditary Hemorrhagic Telangiectasia (HHT);   Epistaxis
Interventions:   Drug: Floseal;   Other: Packing
Sponsors:   St. Michael's Hospital, Toronto;   The Ottawa Hospital
Recruiting - verified January 2017
Ultrasonography in Hemophilic Joint Disease and Serum Markers
Conditions:   Hemophilia A;   Hemophilia B;   Hemarthroses
Intervention:   Other: ultrasound
Sponsors:   Northwell Health;   National Cancer Institute (NCI);   University of California, San Diego
Recruiting - verified July 2017
Study of Voncento® in Subjects With Von Willebrand Disease
Condition:   Von Willebrand Disease
Intervention:   Biological: Voncento
Sponsor:   CSL Behring
Recruiting - verified August 2017
ATHN 2: Factor Switching Study
Condition:   Hemophilia
Interventions:   Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013;   Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Sponsors:   American Thrombosis and Hemostasis Network;   Bioverativ (Biogen);   Shire;   CSL Behring
Recruiting - verified August 2017
A Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) LR769 for the Prevention of Excessive Bleeding in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX Undergoing Elective Surgery or Other Invasive Procedure
Condition:   Hemophilia
Intervention:   Biological: Coagulation Factor VIIa (Recombinant)
Sponsors:   LFB USA, Inc.;   Laboratoire français de Fractionnement et de Biotechnologies
Recruiting - verified January 2017
Swiss Hemophilia Registry
Condition:   Hemophilia and Other Severe Bleeding Disorders
Intervention:   Other: Registry
Sponsor:   Swiss Hemophilia Network
Recruiting - verified March 2017
Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)
Condition:   Von Willebrands Disease
Intervention:  
Sponsors:   Jonathan Roberts;   Blood Center of Wisconsin
Recruiting - verified August 2016
Natural History Study of Factor IX Treatment and Complications
Condition:   Factor IX Deficiency
Intervention:   Other: Standard care with blood and urine sample collection
Sponsors:   Skane University Hospital;   Indiana Hemophilia and Thrombosis Center;   University of Bonn;   Biogen;   Swedish Orphan Biovitrum
Recruiting - verified August 2017
A Gene Therapy Study for Hemophilia B
Condition:   Hemophilia B
Intervention:   Genetic: SPK-9001
Sponsors:   Spark Therapeutics;   Pfizer
Recruiting - verified February 2017
Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
Condition:   Hemophilia A
Intervention:   Drug: Plasma-derived FVIII/VWF concentrate
Sponsors:   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico;   Sintesi Research Srl
Recruiting - verified June 2015
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Condition:   Von Willebrand Disease
Intervention:   Drug: plasma-derived FVIII/VWF concentrate Fanhdi
Sponsor:   Instituto Grifols, S.A.
Recruiting - verified August 2017
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction
Conditions:   Pulmonary Arteriovenous Malformations;   Hereditary Hemorrhagic Telangiectasia;   Asthma;   COPD
Intervention:   Other: Cardiopulmonary exercise test
Sponsor:   Imperial College London
Not yet recruiting - verified April 2015
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
Condition:   Hemophilia
Intervention:  
Sponsor:   Karolinska Institutet
Recruiting - verified March 2017
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa
Conditions:   Hemophilia A With Inhibitors;   Hemophilia B With Inhibitors
Intervention:   Biological: Coagulation FVIIa (Recombinant)
Sponsors:   LFB USA, Inc.;   Laboratoire français de Fractionnement et de Biotechnologies
Recruiting - verified January 2017
A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Conditions:   Hemophilia A;   Hemophilia B
Intervention:   Drug: MOD-5014
Sponsor:   Opko Biologics
Recruiting - verified September 2016
Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency
Condition:   Congenital Fibrinogen Deficiency
Intervention:   Biological: Octafibrin
Sponsor:   Octapharma
Recruiting - verified May 2016
Intranasal Bevacizumab for HHT-Related Epistaxis
Conditions:   HHT;   Hereditary Hemorrhagic Telangiectasia;   Epistaxis;   Nose Bleeds;   Nasal Bleeding
Interventions:   Drug: Bevacizumab;   Drug: Placebo (Saline)
Sponsor:   Stanford University
Recruiting - verified April 2017
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Condition:   Hemophilia A
Intervention:   Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
Sponsor:   Bayer
Recruiting - verified July 2017
To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Intervention:   Drug: turoctocog alfa
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017
Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
Condition:   Congenital Fibrinogen Deficiency
Intervention:   Drug: Octafibrin
Sponsor:   Octapharma
Recruiting - verified May 2016
Development of a Specific Measure for Assessing Adherence in Adult Patients With Hemophilia.
Condition:   Haemophilia
Intervention:  
Sponsor:   Universidad de Murcia
Recruiting - verified September 2015
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Conditions:   Hemophilia A;   Severe Hemophilia A
Intervention:   Biological: rVIII‑SingleChain
Sponsor:   CSL Behring
Recruiting - verified July 2017
Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder
Condition:   Inherited Platelet Disorders
Intervention:   Other: Blood collection for platelet protein samples
Sponsors:   Hadassah Medical Organization;   Hebrew University of Jerusalem
Not yet recruiting - verified February 2016
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Conditions:   Congenital Bleeding Disorder;   Haemophilia B
Intervention:   Drug: nonacog beta pegol
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017
ADVATE Hemophilia A Outcome Database (AHEAD)
Condition:   Hemophilia A
Intervention:   Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Sponsor:   Baxalta US Inc.
Recruiting - verified March 2017
Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
Conditions:   Hemophilia A;   Hemophilia B;   Von Willebrand's Disease
Intervention:  
Sponsors:   Karolinska University Hospital;   The Swedish Society of Medicine;   Karolinska Institutet
Recruiting - verified August 2016
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Condition:   Hemophilia B
Intervention:   Biological: rIX-FP
Sponsor:   CSL Behring
Recruiting - verified July 2017
Willebrand International Non-interventional Global Surveillance
Condition:   Von Willebrand Disease
Intervention:  
Sponsor:   Laboratoire français de Fractionnement et de Biotechnologies
Recruiting - verified March 2016
Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa
Condition:   Haemophilia
Intervention:  
Sponsor:   Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus
Recruiting - verified December 2015
Modifiers of Disease Severity in Cerebral Cavernous Malformations
Conditions:   Cavernous Angioma, Familial;   Cerebral Cavernous Malformations;   Cerebral Cavernous Hemangioma
Intervention:  
Sponsors:   University of New Mexico;   University of California, San Francisco;   Barrow Neurological Institute;   Angioma Alliance;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2016
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Condition:   Hereditary Hemorrhagic Telangiectasia
Interventions:   Drug: Topical timolol maleate;   Drug: placebo saline drops
Sponsors:   St. Michael's Hospital, Toronto;   University of California, San Francisco;   The Hospital for Sick Children;   University of Toronto;   Sunnybrook Health Sciences Centre;   Ryerson University;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2017
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs
Conditions:   Pulmonary Arteriovenous Malformations;   Hereditary Hemorrhagic Telangiectasia
Interventions:   Other: Cardiopulmonary exercise test;   Procedure: Blood test
Sponsor:   Imperial College London
Recruiting - verified October 2015
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A
Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Intervention:   Drug: turoctocog alfa pegol
Sponsor:   Novo Nordisk A/S
Recruiting - verified September 2016
Hemophilia Inhibitor Previously Untreated Patient Study
Condition:   Hemophilia A
Intervention:   Drug: FVIII concentrate
Sponsors:   The University of Texas Health Science Center, Houston;   Rho, Inc.;   Baxter Healthcare Corporation
Recruiting - verified May 2016
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions:   Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
Recruiting - verified August 2017
Thrombocytopathy in Gaucher Disease Patients
Conditions:   Gaucher Disease;   Thrombocytopathy
Intervention:  
Sponsors:   Rabin Medical Center;   Genzyme, a Sanofi Company
Recruiting - verified October 2016
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Conditions:   Thrombotic Thrombocytopenic Purpura;   Congenital Thrombotic Thrombocytopenic Purpura;   Familial Thrombotic Thrombocytopenic Purpura;   Thrombotic Thrombocytopenic Purpura, Congenital;   Upshaw-Schulman Syndrome
Intervention:   Other: Observation
Sponsors:   University Hospital Inselspital, Berne;   Swiss National Science Foundation;   Mach-Gaensslen Foundation Switzerland;   Baxalta Innovations GmbH, Wien, Austria
Recruiting - verified September 2016
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
Condition:   Hereditary Hemorrhagic Telangiectasia
Intervention:  
Sponsors:   St. Michael's Hospital, Toronto;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2017
Registry for Vascular Anomalies Associated With Coagulopathy
Conditions:   Multifocal Lymphangioendotheliomatosis With Thrombocytopenia;   Cutaneovisceral Angiomatosis With Thrombocytopenia;   Vascular Anomaly With Thrombocytopenia;   Hemangiomas
Intervention:   Other: no intervention
Sponsor:   Medical College of Wisconsin
Recruiting - verified March 2017
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
Condition:   Von Willebrand Disease
Intervention:   Biological: Alphanate SD/HT
Sponsor:   Grifols Biologicals Inc.
Recruiting - verified January 2017
Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.
Condition:   Antithrombin III Deficiency
Intervention:   Drug: Plasma-derived AT-III concentrate
Sponsor:   Grifols Biologicals Inc.
Recruiting - verified January 2017
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Condition:   Glanzmann Thrombasthenia
Intervention:  
Sponsors:   Rockefeller University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2016
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
Conditions:   Blood Coagulation Disorders, Inherited;   Thrombotic Disorder
Intervention:  
Sponsor:   The University of Texas Health Science Center, Houston
Recruiting - verified May 2016
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
Condition:   Telangiectasia, Hereditary Hemorrhagic
Intervention:  
Sponsors:   Imperial College London;   British Heart Foundation
Recruiting - verified August 2008
Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
Condition:   Telangiectasia, Hereditary Hemorrhagic
Intervention:  
Sponsors:   Imperial College London;   The Margaret Hayton HHT Fund
Recruiting - verified August 2008
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Conditions:   Albinism;   Intestinal Disease;   Kidney Disease;   Myocardial Disease;   Pulmonary Fibrosis
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified March 9, 2017
http://www.clinicaltrials.gov/ct2/results/rss.xml?&term=Inherited+Bleeding+Disorder&recr=Open&show_rss=Y&count=10000